MetaVia Initiates Phase 1 Trial for DA-1726 in Obesity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 10 2026
0mins
Should l Buy MTVA?
Source: PRnewswire
- Trial Commencement: MetaVia has successfully dosed the first patient in its Phase 1 clinical trial for DA-1726, marking a significant step towards evaluating higher doses safely, which could bring new hope for obesity treatment.
- Dose Optimization Strategy: The trial is divided into two cohorts utilizing one-step and two-step dose escalation strategies aimed at safely achieving therapeutic doses of 48mg and 64mg, potentially enhancing patient tolerability and efficacy significantly.
- Promising Initial Results: At the 48mg dose, patients experienced an average weight loss of approximately 9%, alongside meaningful reductions in waist circumference and improved glycemic control, highlighting DA-1726's potential in treating obesity and related metabolic disorders.
- Future Data Expectations: More data is anticipated in the fourth quarter of 2026, with MetaVia aiming to further demonstrate DA-1726's unique efficacy and competitive advantage in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MTVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MTVA
Wall Street analysts forecast MTVA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.510
Low
40.00
Averages
47.50
High
55.00
Current: 1.510
Low
40.00
Averages
47.50
High
55.00
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MetaVia Initiates Phase 1 Trial for DA-1726 in Obesity
- Trial Commencement: MetaVia has successfully dosed the first patient in its Phase 1 clinical trial for DA-1726, marking a significant step towards evaluating higher doses safely, which could bring new hope for obesity treatment.
- Dose Optimization Strategy: The trial is divided into two cohorts utilizing one-step and two-step dose escalation strategies aimed at safely achieving therapeutic doses of 48mg and 64mg, potentially enhancing patient tolerability and efficacy significantly.
- Promising Initial Results: At the 48mg dose, patients experienced an average weight loss of approximately 9%, alongside meaningful reductions in waist circumference and improved glycemic control, highlighting DA-1726's potential in treating obesity and related metabolic disorders.
- Future Data Expectations: More data is anticipated in the fourth quarter of 2026, with MetaVia aiming to further demonstrate DA-1726's unique efficacy and competitive advantage in the market.
See More
MetaVia Initiates Phase 1 Trial for DA-1726
- Clinical Trial Progress: MetaVia announced that the first patient has been dosed in its Phase 1 clinical trial for DA-1726, marking a significant step towards evaluating higher doses safely, which could provide new solutions for obesity treatment.
- Dose Optimization Strategy: The trial consists of two 16-week cohorts designed to assess one-step and two-step dose escalation strategies aimed at safely achieving higher therapeutic doses, thereby enhancing patient tolerability and efficacy.
- Significant Preliminary Results: At the 48 mg dose, patients experienced an average weight loss of approximately 9%, alongside meaningful reductions in waist circumference and improved glycemic control, indicating DA-1726's potential superiority over existing therapies.
- Future Outlook: More data is expected in the fourth quarter of 2026, as MetaVia focuses on further demonstrating DA-1726's efficacy, aiming for breakthrough advancements in obesity and related metabolic diseases.
See More
MetaVia Reports FY 2025 Financial Results with Significant Losses
- Financial Loss: MetaVia reported a GAAP EPS of -$7.35 for FY 2025, indicating significant challenges in profitability that could undermine investor confidence and future financing capabilities.
- Cash Position: As of December 31, 2025, MetaVia's cash and cash equivalents stood at $10.3 million, down from $16.0 million in 2024, highlighting increased liquidity pressure and the need for careful operational cash management.
- Funding Strategy: The company plans to bolster its finances through an $8.1 million underwritten public offering in January 2026, which is expected to improve cash flow and support operations into Q4 2026, ensuring continued market presence.
- Future Outlook: Despite the current financial difficulties, MetaVia aims to achieve long-term sustainability through new financing and operational efficiency improvements; however, ongoing losses may negatively impact its competitive position in the market.
See More
MetaVia Reports Phase 1 Data for DA-1726 Indicating Best-in-Class Potential
- Clinical Data Highlights: MetaVia's Phase 1 trial of DA-1726 at 48 mg demonstrated a 9.1% weight loss, significant improvements in glucose control, and direct liver benefits, indicating its best-in-class potential for treating obesity and related metabolic disorders.
- Improved Financial Position: The company raised $9.3 million through a public offering in January 2026, which is expected to fund the advancement of the DA-1726 program and sustain operations into the fourth quarter of 2026.
- Research Plan Update: With Institutional Review Board approval secured, the company plans to initiate a 16-week titration study for DA-1726 in April 2026, evaluating both 48 mg and 64 mg regimens, with data anticipated in the fourth quarter of 2026.
- Intellectual Property Protection: DA-1726 is supported by 39 granted and pending patents, ensuring protection in the U.S. and internationally at least through 2041, which further strengthens its competitive position in the market.
See More
MetaVia Unveils DA-1726 Phase 1 Data, Showcasing Best-in-Class Potential
- Clinical Data Highlights: MetaVia announced Phase 1 data for DA-1726 showing a 9.1% weight loss, significant improvements in glucose control, and liver health benefits, indicating its best-in-class potential for treating obesity and related metabolic disorders.
- Improved Financial Position: The company raised $9.3 million in a public offering in January 2026, expected to fund the advancement of the DA-1726 program and ensure operational cash flow through the fourth quarter of 2026.
- Intellectual Property Protection: MetaVia has established a robust intellectual property portfolio with 39 and 48 patents for DA-1726 and vanoglipel, respectively, ensuring competitive advantages in global markets with protection extending to 2041 and 2035.
- Future Clinical Plans: The company plans to initiate a Phase 1 Part 3, 16-week titration study for DA-1726 in April 2026, with data expected in the fourth quarter of 2026, further validating its efficacy in obesity treatment.
See More
META'S ANDY STONE RESPONDS TO LA VERDICT: WE DISAGREE AND PLAN TO APPEAL - X POST
- Meta's Response: Meta has expressed disagreement with the recent verdict and plans to appeal the decision.
- Legal Context: The statement indicates that Meta respects the legal process but does not agree with the outcome of the case.
See More
MetaVia Initiates Phase 1 Trial for DA-1726 in Obesity
- Trial Commencement: MetaVia has successfully dosed the first patient in its Phase 1 clinical trial for DA-1726, marking a significant step towards evaluating higher doses safely, which could bring new hope for obesity treatment.
- Dose Optimization Strategy: The trial is divided into two cohorts utilizing one-step and two-step dose escalation strategies aimed at safely achieving therapeutic doses of 48mg and 64mg, potentially enhancing patient tolerability and efficacy significantly.
- Promising Initial Results: At the 48mg dose, patients experienced an average weight loss of approximately 9%, alongside meaningful reductions in waist circumference and improved glycemic control, highlighting DA-1726's potential in treating obesity and related metabolic disorders.
- Future Data Expectations: More data is anticipated in the fourth quarter of 2026, with MetaVia aiming to further demonstrate DA-1726's unique efficacy and competitive advantage in the market.
See More
MetaVia Initiates Phase 1 Trial for DA-1726
- Clinical Trial Progress: MetaVia announced that the first patient has been dosed in its Phase 1 clinical trial for DA-1726, marking a significant step towards evaluating higher doses safely, which could provide new solutions for obesity treatment.
- Dose Optimization Strategy: The trial consists of two 16-week cohorts designed to assess one-step and two-step dose escalation strategies aimed at safely achieving higher therapeutic doses, thereby enhancing patient tolerability and efficacy.
- Significant Preliminary Results: At the 48 mg dose, patients experienced an average weight loss of approximately 9%, alongside meaningful reductions in waist circumference and improved glycemic control, indicating DA-1726's potential superiority over existing therapies.
- Future Outlook: More data is expected in the fourth quarter of 2026, as MetaVia focuses on further demonstrating DA-1726's efficacy, aiming for breakthrough advancements in obesity and related metabolic diseases.
See More
MetaVia Reports FY 2025 Financial Results with Significant Losses
- Financial Loss: MetaVia reported a GAAP EPS of -$7.35 for FY 2025, indicating significant challenges in profitability that could undermine investor confidence and future financing capabilities.
- Cash Position: As of December 31, 2025, MetaVia's cash and cash equivalents stood at $10.3 million, down from $16.0 million in 2024, highlighting increased liquidity pressure and the need for careful operational cash management.
- Funding Strategy: The company plans to bolster its finances through an $8.1 million underwritten public offering in January 2026, which is expected to improve cash flow and support operations into Q4 2026, ensuring continued market presence.
- Future Outlook: Despite the current financial difficulties, MetaVia aims to achieve long-term sustainability through new financing and operational efficiency improvements; however, ongoing losses may negatively impact its competitive position in the market.
See More
MetaVia Reports Phase 1 Data for DA-1726 Indicating Best-in-Class Potential
- Clinical Data Highlights: MetaVia's Phase 1 trial of DA-1726 at 48 mg demonstrated a 9.1% weight loss, significant improvements in glucose control, and direct liver benefits, indicating its best-in-class potential for treating obesity and related metabolic disorders.
- Improved Financial Position: The company raised $9.3 million through a public offering in January 2026, which is expected to fund the advancement of the DA-1726 program and sustain operations into the fourth quarter of 2026.
- Research Plan Update: With Institutional Review Board approval secured, the company plans to initiate a 16-week titration study for DA-1726 in April 2026, evaluating both 48 mg and 64 mg regimens, with data anticipated in the fourth quarter of 2026.
- Intellectual Property Protection: DA-1726 is supported by 39 granted and pending patents, ensuring protection in the U.S. and internationally at least through 2041, which further strengthens its competitive position in the market.
See More
MetaVia Unveils DA-1726 Phase 1 Data, Showcasing Best-in-Class Potential
- Clinical Data Highlights: MetaVia announced Phase 1 data for DA-1726 showing a 9.1% weight loss, significant improvements in glucose control, and liver health benefits, indicating its best-in-class potential for treating obesity and related metabolic disorders.
- Improved Financial Position: The company raised $9.3 million in a public offering in January 2026, expected to fund the advancement of the DA-1726 program and ensure operational cash flow through the fourth quarter of 2026.
- Intellectual Property Protection: MetaVia has established a robust intellectual property portfolio with 39 and 48 patents for DA-1726 and vanoglipel, respectively, ensuring competitive advantages in global markets with protection extending to 2041 and 2035.
- Future Clinical Plans: The company plans to initiate a Phase 1 Part 3, 16-week titration study for DA-1726 in April 2026, with data expected in the fourth quarter of 2026, further validating its efficacy in obesity treatment.
See More
META'S ANDY STONE RESPONDS TO LA VERDICT: WE DISAGREE AND PLAN TO APPEAL - X POST
- Meta's Response: Meta has expressed disagreement with the recent verdict and plans to appeal the decision.
- Legal Context: The statement indicates that Meta respects the legal process but does not agree with the outcome of the case.
See More
